In this episode of The Insight, Jerry Lee, a managing director in the Global Healthcare Investment Banking Group, discusses how the golden age of biotechnology and the current capital raising environment has created a disconnect in the market’s ability to fund new innovation across the sector. Although the current macro environment has made public markets funding challenging overall, with biopharma is no exception – the outlook for both capital raising & strategic M&A in 2023 is more positive.
Source: Dealogic and CapIQ as of 9-Dec-22
Our signature newsletter with insights and analysis from across the firm
By submitting this information, you agree that the information you are providing is subject to Goldman Sachs’ privacy policy and Terms of Use. You consent to receive our newletter via email.